Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity.
Industry: Health Care
Latest Trade: $30.58 0.00 (0.0%)
First Day Return: +47.2%
Return from IPO: +69.9%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/10/2025 |
Offer Price | $18.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 15.3 |
Deal Size ($mm) | $275 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/30/2025 |
Offer Price | $18.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 15.3 |
Deal Size ($mm) | $275 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
BofA Securities |
Goldman Sachs |
more |
Company Data | |
---|---|
Headquarters | New York, NY, United States |
Founded | 2022 |
Employees at IPO | 81 |
Website www.metsera.com |